retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished The trial that put “24%”

They have been shown to have an anti-inflammatory effect - both mechanical as well as biochemical in inhibiting phagocytosis, reducing levels of prostaglandins, interleukin 1, free radicals and cyclic AMP

Tissue Repair Peptide Body Protection Compound BPC-157 is a synthetic peptide derived from a protective protein in the stomach, known for its remarkable tissue healing properties

In group B, vacuoles were clearly evident, and the number of sperm was very low

If you want the deeper science on how the two work together, see our primer on prebiotics, probiotics, and synbiotics

P grund av tilltagande psykomotorisk oro och agitation sederades patienten med propofol samt intuberades och vrdades i respirator ver natten

Libido is a brain-driven process powered by dopamine signaling